A few clinical statistical observations on the use of Solganal-B-Oleosum n bronchial asthma.
In my clinic, Solganal-B-Oleosum was administered to the patients with bronchial asthma from 1955 up to 1973, covering a period of 19 years, and statistical observation has been done. Several clinical results are presented. 1) In 1,056 cases, markedly improved 40.8%, improved 32.8%; clinically effective ratio: total 73.6%. Others: a few somewhat improved and unimproved cases, then inconsiderable aggravated cases. 2) The longer the period from the age of onset to the beginning of treatment, the lower the efficiency; the shorter the period, the higher the efficiency. 3) The group of light severity revealed high efficiency; and according to the grade of severity the efficiency decreased. 4) Sex, age, age of onset, disposition of asthma, etc., resulted in no clear relation to the effectiveness. 5) Side effect revealed 2.3% skin eruption, and then a few cases of proteinuria, stomatitis, gingivitis, etc. There was no case of severe, critical disorder. 6) In other cases, long-term effectiveness after finishing the Solganal treatment was pursued. A trial of additional injection for several years after finishing the treatment was also studied. Serum gold concentrations in the course and after finishing the main course etc., were measured.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000401:mortality; D006051:Aurothioglucose / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006046:Gold / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013223:Statistics as Topic; D013997:Time Factors
D006051:Aurothioglucose; D006046:Gold